

**FILED**  
**SAN MATEO COUNTY**

MAY 11 2021

Clerk of the Superior Court

By

  
DEPUTY CLERK

IN THE SUPERIOR COURT OF THE STATE OF CALIFORNIA

IN AND FOR THE COUNTY OF SAN MATEO

JASON WIENER, an individual; and DARRELL  
RODRIGUEZ, an individual,

Plaintiffs,

v.

STEPHANIE STONE; NICHOLAS STONE; IRIS  
REYES; and DOES 1-100, Inclusive,

Defendants,

Case No. 18Civ00255

**TENTATIVE RULINGS ON MOTIONS IN  
LIMINE**

Date: May 17, 2021

Time: 2:00 p.m.

Dep't: 4

Judge: Hon. Nancy L. Fineman

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**Motion in Limine 13**

**Disclosure**

On April 21, 2021, the Department 4 clerk sent an email to counsel advising them that Judge Fineman’s daughter-in-law’s sister is a neurosurgeon at an out-of-state hospital. Judge Fineman does not believe, based upon a quick search that the doctor has written on DTI-MRI, but her webpage at the

1 hospital lists publications that deal with MRIs, brain tumors and other issues. Judge Fineman has not  
2 read any of her articles or had any substantive discussions with her about her work. The name of the  
3 doctor and the hospital for which she works was disclosed in the email. For privacy purposes, Judge  
4 Fineman does not disclose that information in this public record.

### 5 **The Parties' Overview Arguments and the *Kelly* Test**

6  
7 Defendant seeks to preclude Plaintiff from introducing any evidence or mentioning DTI-MRI  
8 testing or imaging or the results of tests performed on Plaintiff. Defendant argues that DTI-MRI is a  
9 “recognized tool for research but has been deemed not to be reliable for use in individual patients with  
10 suspected traumatic brain injury – the very type of injury Plaintiff is attempting to prove via DTI-MRI  
11 imaging.” Defendants' Motion in Limine No. 13 at 2. Plaintiff argues that DTI-MRI has been in use  
12 since 1994, the Food and Drug Administration approved DTI-MRI for marketing in 2001 and courts have  
13 overwhelmingly rejected Defendants' arguments. Plaintiff's Opposition at 2. If the DTI-MRI evidence is  
14 used in conjunction with other medically accepted evidence which supports the diagnosis, *Ruppel v.*  
15 *Kucanin* (N.D. Ind., June 20, 2011, No. 3:08 CV 591) 2011 WL 2470621, the Court confirms the  
16 substance of the articles it requests Plaintiff provide, and Plaintiff supplies the foundation for the 10  
17 expert declarations, the motion is DENIED.

18  
19 Defendants correctly rely on *Sargon* that “the trial court acts as a gatekeeper to exclude expert  
20 opinion testimony that is (1) based on matter of a type on which an expert may not reasonably rely, (2)  
21 based on reasons unsupported by the material on which the expert relies, or speculative.” *Sargon*  
22 *Enterprises, Inc. v. University of Southern California* (2012) 55 Cal.4th 747, 771–772 relying on  
23 Evidence Code §§ 801(b) and 802; *id.* at 770. Plaintiff explains that: “Expert testimony deduced from  
24 novel scientific principles may be admissible if the proponent of the evidence makes a ‘preliminary  
25 showing of general acceptance of the new technique in the relevant scientific community.’” Plaintiff's  
26  
27  
28

1 Opposition at 4 quoting *People v. Kelly* (1976) 17 Cal.3d 24<sup>1</sup> The burden to establish the *Kelly* factors is  
2 on the proponent of the evidence. *Id.* at 612. As Justice Mark Simons explains, Plaintiff must establish:

- 3 • The reliability of the method must be established, usually by expert testimony;
- 4 • The witness furnishing such testimony must be properly qualified as an expert to give an  
5 opinion on the subject; and
- 6 • The proponent of the evidence must demonstrate that correct scientific procedures were  
7 used in the particular case.<sup>2</sup>

8 Simons *California Evidence Manual* § 4:27 (2021). “General acceptance” under *Kelly* means a consensus  
9 drawn from a typical cross-section of the relevant, qualified scientific community. *People v. Leahy* (1994) 8  
10 Cal.4th 587, 612. “With respect to the first prong of this test, reliability means that the technique must be  
11 sufficiently established to have gained general acceptance in the particular field in which it belongs. In  
12 determining whether there has been general acceptance, the goal is not to decide the actual reliability of  
13 the new technique, but simply to determine whether the technique is generally accepted in the relevant  
14 scientific community. Courts must consider the quality, as well as quantity, of the evidence supporting  
15 or opposing a new scientific technique. Mere numerical majority support or opposition by persons  
16 minimally qualified to state an authoritative opinion is of little value.” *People v. Morganti* (1996) 43  
17 Cal.App.4th 643, 656 (internal citations, quotations and brackets omitted).

### 18 **The Court Applies the *Kelly* Test to DTI-MRI**

19  
20 “*Kelly* applies only to that limited class of expert testimony which is based, in whole or in part, on  
21 a technique, process, or theory which is *new* to science and, even more so, to the law.” *People v. Cowan*  
22 (2010) 50 Cal.4th 401, 470 (emphasis in original; internal quotations and citations omitted). The parties  
23 appear to agree that the *Kelly* standard applies to the DTI-MRI testing. Therefore, the Court assumes that  
24

25  
26 \_\_\_\_\_  
27 <sup>1</sup> *Kelly* is still the controlling law in California. *Sargon*, 55 Cal.4th at 772, n. 6.

28 <sup>2</sup> Defendants have not challenged this third prong, that the correct scientific procedures were not used  
in this case.

(continued . . .)

1 it must apply the *Kelly/Sargon* analysis. Since Plaintiff does not argue to the contrary, the Court also  
2 assumes that the DTI-MRI is not an improvement of the MRI, which would make the *Kelly* analysis  
3 unnecessary. *People v. Cordova* (2015) 62 Cal.4th 104, 128.<sup>3</sup>

4  
5 If a California appellate court has approved the scientific method, then the Court does not need to  
6 conduct a *Kelly* hearing. *Kelly*, 17 Cal.3d at 32. The Court may look at decisions from other  
7 jurisdictions and relevant scientific literature in determining whether a technique is generally accepted.  
8 *Kelly* at 35; *People v. Allen* (1999) 72 Cal.App.4th 1093, 1099.

9 The Court should review the scientific literature and may rely solely on the scientific literature to  
10 conclude that there is no generally accepted scientific consensus about the reliability of the new  
11 technique at that time. *Kelly*, 17 Cal.3d at 35 (“Such writings may be considered by courts in evaluating  
12 the reliability of new scientific methodology”); *In re Jordan R.* (2012) 205 Cal.App.4th 111, 128 citing  
13 *Leahy*, 8 Cal.4th at 611; *Shirley*, 31 Cal.3d at (“if a fair overview of the literature discloses there is  
14 significant public opposition to the technique as unreliable, the court may rely on the literature alone to  
15 conclude there is no general consensus at the present time”). *People v. Morganti* (1996) 43 Cal.App.4th  
16 643, 665 (“As our Supreme Court has recently confirmed, *Kelly* does not demand absolute unanimity of  
17 views in the scientific community. If a fair overview of the literature discloses that scientists significant  
18 either in number or expertise publicly oppose the technique as unreliable, the court may safely conclude  
19 there is no such consensus at the present time.” (citations, internal quotations, brackets omitted)).

20  
21  
22 A court may also rely on disinterested experts regarding the technique’s general acceptance in the  
23 relevant community. *In re Jordan R.* (2012) 205 Cal.App.4th 111, 130 citing authorities. “A witness  
24 qualifying as an expert is *disinterested* if he is not ‘so personally invested in establishing the technique’s  
25

26  
27 <sup>3</sup> Neither party has cited to a case finding that diagnostic medical imaging is admissible. However, the  
28 Supreme Court has analyzed the qualifications concerning MRIs suggesting that testimony regarding  
MRIs is permissible. *People v. Pearson* (2013) 56 Cal.4th 393, 445.

1 acceptance that he might not be objective about disagreements within the relevant scientific  
2 community.” *Id.* (emphasis in original) quoting *People v. Brown* (1985) 40 Cal.3d 512, at 530. The  
3 expert does not have to be totally disinterested; “a certain degree of “interest must be tolerated if scientists  
4 familiar with the theory and practice of a new technique are to testify at all.” *People v. Morganti* (1996)  
5 43 Cal.App.4th 643, 667.

### 7 **The Evidence Submitted by the Parties**

#### 8 **Defendants’ Evidence**

9 In support of their motion, Defendants submit six exhibits: (1) portions of a publication from the  
10 American College of Radiologists; (2) a law review article; (3) 3 pages from a Veteran’s Affairs and  
11 Department of Defense publication; (4) a statement by the Radiological Society of North American; (5)  
12 portions of plaintiff’s expert radiologist Murray Solomon, M.D. deposition; and (6) portions of plaintiff’s  
13 expert neurologist Mark D’Esposito. M.D deposition.  
14

#### 15 **Plaintiff’s Evidence**

16 In support of his motion, Plaintiff submits: (1) Declaration of Murray Solomon M.D., Plaintiff’s  
17 expert radiologist, which attaches as exhibits his CV, a 2013 article entitled, “A Decade of DTI in  
18 Traumatic Brain Injury: 10 Years and 100 Articles Later” and a 2014 article entitled “Clarifying the  
19 Robust Foundation for and Appropriate Use of DTI in mTBI Patients;” and (2) an attorney declaration  
20 that includes portions of the deposition of Jerome Barakos, M.D., Defendants’ neuroradiologist, portions  
21 of the deposition of Mark D. Esposito, M.D., Plaintiff’s neurologist, portions of deposition of David  
22 Patterson, M.D., Plaintiff’s physiatrist; 27 state and federal orders across the nation allowing DTI-MRI  
23 testimony and 10 declarations of physicians who confirm DTI-MRI is reliable and useful. The Court  
24 notes that Plaintiff fails to provide any analysis or highlighting of these orders and declarations. The  
25 Court cautions Plaintiff’s counsel that in the future they should not depend on the trial court having the  
26 time to spend as much time as this Court was able to during a Pandemic staycation to review the  
27  
28

1 materials. Instead, it is incumbent upon the attorneys to provide the information to the Court in a well-  
2 organized and analytical manner rather than simply providing the underlying material to the Court.

### 3 **Court's Analysis**

#### 4 **Case Law**

5 There has been no California appellate authority that has ruled on the admissibility of DTI-MRI.  
6 None of Plaintiff's attached orders, save one, are from an appellate court<sup>4</sup>—they are all out-of-state or  
7 federal trial court orders. Plaintiff does not discuss or attach any of the cases where courts have denied  
8 the admissibility of DTI-MRI. Defendants only citation to other court's ruling is through the University  
9 of Cincinnati Law Review article published in 2018. The articles appear to only list cases where the  
10 courts have admitted the DTI-MRI evidence. Andrew M. Lehmkuhl II, Diffusion Tensor Imaging:  
11 Failing Daubert & Fed. R. Evid. 702 in Traumatic Brain Injury Litigation, 87 *U. Cin. L. Rev.* 279,283  
12 (2018) at 298, n. 150, 151. In affirming a death sentence, the Ohio Supreme Court referred to three brain  
13 scans, including "an MRI diffusion tensor imaging ("DTI") scan", but there is no affirmation of the use  
14 of the test. *State v. Kirkland* (2020) 160 Ohio St.3d 389, 417, reconsideration denied (2020) 160 Ohio  
15 St.3d 1421 (case found through Court's research; not cited by the parties). In the Court's Westlaw  
16 research, there are only three California trial court cases on DTI-MRI, all in the motion in limine context,  
17 but none of orders contain a substantive ruling. *Rivera v. PCH Beach Resort, LLC*, (Aug. 6, 2019 Cal.  
18 Super.) 2019 WL 8438465, at \*1 ("MIL13 to exclude evidence of diffusion tensor imaging (DTI) studies  
19 is reserved as E.C. 402 hearing is required.")<sup>5</sup>; *Camacho v. Brentwood Holdings Partners LLC*  
20 (Cal.Super. Feb. 1, 2018) 2018 WL 3304510, at \*2 ("Defendant's #16 to Exclude Evidence of Non  
21  
22  
23  
24  
25

26 <sup>4</sup> The appellate court opinion is not designated for publication. *LeBoeuf v. B&K Contractors, Inc.* (4th  
27 Cir. May 27, 2009) 2009 La.App. Unpub. Lexis 324; 2009 WL 8688909.

28 <sup>5</sup> This case went to jury verdict. *Rivera v. PCH Beach Resort, LLC* (Cal.Super. Aug. 5, 2019) 2019 WL  
8438461, at \*1 (judgment).

1 Disclosed Medical Doctor, Aaron Filler, M.D., and any reference to His Undisclosed DTI MRI of the  
2 Brain is RESERVED.”); *Morales v. Harris* (Cal.Super. Oct. 18, 2018) 2018 WL 7077590, at \*2 (Motion  
3 in Limine No. 15 For Order to Conduct a Hearing Out of the Presence of the Jury to Determine the  
4 Admissibility of the DTI MRI and Opinions and Findings Relative Thereto - Denied.”).

5 **In most of the orders submitted by Plaintiff, the courts do not analyze the scientific articles**  
6 **supporting the reliability of DTI-MRI. An exception is ” *Ruppel v. Kucanin* (N.D. Ind., June 20, 2011,**  
7 **No. 3:08 CV 591) 2011 WL 2470621.**

8  
9 The cases cited by the parties are several years old. The Court’s research finds that more recent  
10 cases further demonstrate that motion to exclude the DTI-MRI has been denied or the DTI-MRI evidence  
11 has been considered without objection. See e.g. *Kim v. Stewart* (S.D.N.Y., Mar. 23, 2021, No. 18 CIV.  
12 2500 (SLC)) 2021 WL 1105564, at \*2 (summary judgment motion where plaintiff introduced doctor’s  
13 review of MRI diffusion tensor imaging study which indicated injury); *Woods v. Saul* (S.D.N.Y., Mar. 5,  
14 2021, No. 1:19-CV-0336S(SN)) 2021 WL 848722, at \*6 (Social Security Commission decision refers to  
15 MRI and diffusion tensor imaging of the brain showing no acute intracranial abnormality and had  
16 unremarkable DTI maps but recommendation for additional testing for a possible traumatic brain injury);  
17 *Lance Meadors v. D’Agostino* (M.D. La., Oct. 29, 2020, No. CV 18-01007-BAJ-EWD) 2020 WL  
18 6342637, at \*4 (denying defendant’s motion to exclude DTI on the basis on unreliability); *Shuchun Li v.*  
19 *Harper* (Ohio Com.Pl. Aug. 17, 2020) 2020 WL 9256903 (denying motion to exclude DTI testimony);  
20 *Johnson-Borman v. Taylor* (Ind.Super. Feb. 26, 2020) 2020 WL 4034902, at \*1 (motion to exclude  
21 results of diffusion tensor imaging denied).

22  
23  
24 The Court’s research has only found one case where DTI-MRI was found unreliable and  
25 excluded. *Malone v. Taylor* (Tenn.Cir.Ct. 2019) 2019 WL 6456250, at \*3–5.<sup>6</sup>

26  
27  
28 <sup>6</sup> The Court used its best efforts to discover cases where courts exclude the testimony based on unreliability, but may have missed cases.



1 While the trial court orders are helpful to this Court, they are not precedential authority and this  
2 Court does not read *Kelly* and its progeny as allowing this Court to rely on these trial court decisions.  
3 *Simons California Evidence Manual* § 4:29 (2020) (“no hearing need be held if another trial court has  
4 already admitted such evidence and that decision has been affirmed on appeal by a published decision.”).  
5 Thus, to comply with *Kelly*, the Court must conduct its own analysis rather than rely on other court’s  
6 rulings.

## 8 Articles

### 9 Defendants’ Articles

10 Defendants attach portions of two articles to an attorney declaration, a law review article and a  
11 criteria analysis.

12 While the law review article, Exhibit 2 to the Declaration of Denise Billups-Sloane, provides  
13 criticism of the case law, there is no identifying information about the author, he does not appear to be a  
14 medical expert, and there is no underlying expert analysis of the DTI-MRI testing.

15 Exhibit 1 to the Declaration of Denise Billups-Sloane is the American College of Radiology ACR  
16 Appropriateness Criteria, date of original review 1996, date of last review 2015. Defendants state it  
17 states the use and limitation of DTI-MRI imaging. However, there is no explanation on how to interpret  
18 the chart, no support for the conclusions and no information about the American College of Radiology.

19 Defendants submit as Exhibit 3 to the Declaration of Denise Billups-Sloane two pages of a 133-  
20 page Veteran Administration Practice Guideline. The article is attached to an attorney declaration and  
21 there are no facts, principles or methodologies supporting the conclusions. The article, apparently from  
22 2016, refers to significant methodological problems with DTI studies as well as control problems and  
23 that the DTI findings have not been linked to clinical presentations or outcomes. However, Defendants  
24 have provided no analysis from the article for the Court to analyze the reasonableness of these  
25 statements. Another part of the military apparently holds a different view. “[T]he United States Army  
26  
27  
28

1 Telemedicine and Advanced Technology Research Command (“TATRC”) sponsored a ‘Diffusion MRI  
2 TBI Roadmap Development Workshop’ at which it was acknowledged: “DTI has detected abnormalities  
3 associated with brain trauma at several single centers.’ It was also stated that ‘the workshop seeks to  
4 identify and remove barriers to rapid translation of advanced diffusion MRI technology for TBI ... in  
5 order to expedite getting the benefits of diffusion MRI to reach those who need it most, especially injured  
6 soldiers and veterans.’” *Ruppel v. Kucanin* (N.D. Ind., June 20, 2011, No. 3:08 CV 591) 2011 WL  
7 2470621, at \*7 (citing plaintiff’s expert).<sup>7</sup>

9 Defendants also submit as Exhibit 4 to the Declaration of Denise Billups-Sloane a statement as by  
10 the Radiological Society of North America dated April 15, 2017 that provides: “At present, there is  
11 insufficient evidence supporting the routine clinical use of these advanced neuroimaging techniques for  
12 diagnosis and/or prognostication at the individual patient level.” (emphasis in original). Once again,  
13 there are no facts, principles or methodologies supporting this conclusion and Defendants provide no  
14 information about this Radiological Society.

16 The Court concludes from Defendants’ submission that some experts do not believe that DTI-  
17 MRI is reliable in clinical settings, but finds that these experts constitute significant amount of public  
18 opposition in light of the articles discussed below.

#### 20 **Plaintiff’s Articles**

21 Attached to Plaintiff’s expert Solomon’s declaration are two articles. This Court agrees that the  
22 “A Decade of DTI” article is a literature review and noted the same problems that the court in *Malone v.*  
23 *Taylor* (Tenn.Cir.Ct. 2019) 2019 WL 6456250 discussed. However, the Court’s review of the expert  
24 opinions presented in this case and the explanation of the scientific literature rebut the criticisms.

---

28 <sup>7</sup> This order was one attached to Plaintiff’s motion. The Court cites the Westlaw cite.

1 The article discusses the number of peer-reviewed articles supporting the reliability of DTI-MRI,  
2 but there are no facts, principles or methodologies supporting the conclusions. Peer review is the chief  
3 way to demonstrate scientifically valid principles. *Metabolife Intern., Inc. v. Wornick* (9th Cir. 2001) 264  
4 F.3d 832, 841 (applying *Daubert* standard). Many of the courts in the orders Plaintiff submits rely on the  
5 “A Decade of DTI article”. See e.g. *Marsh v. Celebrity Cruises* at 7; *White v. Deere & Company* at 6.  
6 Defendants provide no information about whether any of their authorities have been peer reviewed.  
7

8 Plaintiff’s articles also do not provide the basis for the conclusions reached or provide any  
9 information about the qualifications of the authors.

10 However, the orders Plaintiff provided and their expert declarations analyze the underlying  
11 articles and other factors demonstrating reliability. Therefore, the Court turns to those authorities.

#### 12 **Articles Cited in Cases and Expert Opinions**

13  
14 As a preliminary matter, the Court finds significant that the Food and Drug Administration has  
15 approved use of DTI-MRI.<sup>8</sup>

16 [I]n 2001, the Food and Drug Administration (“FDA”) approved the product “Diffusion  
17 Tensor Imaging Option for MRI” for marketing as a Class II Special Control device. (Pl.’s Exh. 8,  
18 DE # 57–8.) Ruppel, citing to 21 U.S.C. § 360c(a)(3)(A), states that the FDA tested the software  
19 for safety and effectiveness before granting marketing permission. (DE # 57 at 21.) The letter  
from the FDA does not say this specifically. However, 21 U.S.C. § 360c(a)(3)(A) provides that  
approved Special Control devices are determined to be effective:

20 on the basis of well-controlled investigations, including 1 or more clinical investigations  
21 where appropriate, by experts qualified by training and experience to evaluate the effectiveness of  
22 the device, from which investigations it can fairly and responsibly be concluded by qualified  
23 experts that the device will have the effect it purports or is represented to have under the  
conditions of use prescribed, recommended, or suggested in the labeling of the device.

24 So although the FDA letter itself does not address the effectiveness of DTI, but its  
25 approval for marketing by the FDA indicates that its effectiveness was determined pursuant to 21  
26 U.S.C. § 360c(a)(3)(A). In fact, other courts that have found DTI to be a reliable method have  
noted that it is “FDA approved, peer reviewed and approved, and a commercially marketed  
modality which has been in clinical use for the evaluation of suspected head traumas including

27  
28 <sup>8</sup> See *Geffcken v. D’Andrea* (2006) 137 Cal.App.4th 1298, 1310 (the procedure had not been evaluated  
or approved by the Food and Drug Administration).

1 mild traumatic brain injury.” *Hammar v. Sentinel Ins. Co., Ltd.*, No. 08–019984 at \*2  
2 (Fla.Cir.Ct.2010).

3 *Ruppel v. Kucanin* (N.D. Ind., June 20, 2011, No. 3:08 CV 591) 2011 WL 2470621, at \*7

4 It is reported that there are specific peer-reviewed articles showing that DTI on the effectiveness  
5 of DTI, thus refuting one of the criticisms of the reliability of DTI. *Ruppel v. Kucanin* (N.D. Ind., June  
6 20, 2011, No. 3:08 CV 591) 2011 WL 2470621, at \*9 citing Michael Lipton, Diffusion–Tensor Imaging  
7 Implicates Prefrontal Axonal Injury in Executive Function Impairment Following Very Mild Traumatic  
8 Brain Injury, *Radiology*, Sept. 2009, Vol. 252: No. 3 and Calvin Lo, Diffusion Tensor Imaging  
9 Abnormalities in Patients with Mild Traumatic Brain Injury and Neurocognitive Impairment, *Comput*  
10 *Assist TOMogr*, March/April 2009, Vol. 33, No. 2; *Marsh v. Celebrity Cruises, Inc.* (S.D. Fla., Dec. 15,  
11 2017, No. 1:17-CV-21097-UU) 2017 WL 6987718, at \*4 & n. 3 (citing the same articles); Declaration of  
12 Joseph C. Wu ¶¶ 10-12, 16 citing Miles et al. 2008, Inglese, M. et al. (2005) “Diffuse axonal injury in  
13 mild traumatic brain injury: a diffusion tensor imaging study, 103 *J. of Neurosurgery* 298-303 (Aug.  
14 2005), Abraham, A., “Admissibility of Diffusion Tensor Imaging;” “Mild Traumatic Brain Injury  
15 Assessment with Diffusion Tensor Imaging (DTI) and Positron Emission Tomography (PET\_ scan  
16 finding and Neuropsychological Tests of Cognition and Attention” (peer reviewed presentation by Wu);  
17 Erin David Bigler Declaration ¶¶ 8, 12 citing Aoki et al, Diffusion tensor imaging studies of mild  
18 traumatic brain injury: a meta-analysis, *J. Neurol Neurosurg Psychiatry* 2021 Sep; 83(9); 870-6, Hellyer  
19 et al. Individual prediction of white matter injury following traumatic brain injury *Ann Neurol* 2012 Nov  
20 29 doi 10.1002/ana.23834; Bozzali et al. white matter integrity assessed by diffusion tensor tractography  
21 in a patient with a larger tumor mass but minimal clinical and neuropsychological deficits *Functional*  
22 *Neurology*, 2012, Oct.-Dec; 27(4); 239-246. Bigler also states that the National Institute of Health and  
23 the Department of Defense sponsor the use of DTI and that the webpage of the Defense and Veterans  
24 Brain Injury Center outlines the use of DTI in the evaluation of mTBI, [www.dvbic.org](http://www.dvbic.org), but the Court  
25 could not find the website. *Id.* at ¶9. William W. Orrison, Jr. M.D. lists numerous articles and studies  
26  
27  
28

1 showing that there is a known potential error rate and the existence and maintenance of standards  
2 controlling DTI. Declaration of William W. Orrison, Jr. M.D. ¶13. He also discusses the public  
3 guidelines for operation and interpretation of DTI and peer-review medical literature with a single  
4 subject citing to Krishna, Giordano, et al. and Gold, MM, Lipton, ML, Neurological Picture: Diffusion  
5 Tractography of axonal degeneration following shear injury, J. Neurol Neurosurg, 2008; 79:1374-75. Id.  
6 ¶15-16.

8 There are articles cited with different conclusions. Some of the cases also refer to a November  
9 2014 article by Wintermark *et al.* that finds DTI to be suitable only for research but not routine clinical  
10 use at the individual patient level. See *White v. Deer & Company* (submitted by Plaintiff) at 6.<sup>9</sup>

11 The Court was unable to find these documents online and requests that Plaintiff provide them to  
12 the Court (and opposing counsel) so that the Court can review the articles. If there are any of the 112  
13 articles identified in the “A Decade of DTI” that any party wants the Court to review, those articles shall  
14 be provided. However, the conclusion that the Court draws from commentary about these articles is that  
15 the consensus of the scientific community is that DTI-MRI is reliable in a clinical setting.

### 17 **Experts**

18 Defendants provide no expert declarations. They attach portions of depositions from two of  
19 Plaintiff’s experts. The Court does not agree with the characterization of the testimony provided by  
20 Defendants.  
21

22 Plaintiff provides portions of deposition excerpts from this case, including three of his experts and  
23 a defense neuroradiologist expert, Jerome Barakos, M.D. who testified that he has used MRI DTI for  
24  
25

---

26 <sup>9</sup> See M. Wintermark et al., American College of Radiology Head Injury Institute, Imaging Evidence  
27 and Recommendations for Traumatic Brain Injury: Advanced Neuro- and Neurovascular Imaging  
28 Techniques, in 36 Am. J. Neuroradiology 1 (2015), <https://pdfs.semanticscholar.org/a951/cafd3b64d005cf27da048c8b80ab7baa34e.pdf>, published on behalf of the American College of Radiology Head Injury Institute cited by *Malone v. Taylor* (Tenn.Cir.Ct. 2019) 2019 WL 6456250.

1 over 15 years in 40 different clinical trials and that it can be useful when used in the appropriate fashion  
2 Declaration of Jonathan C. Harriman, Exhibit A at 48-49.

3 Plaintiff's expert Solomon represents that he along with well recognized centers "utilize the same  
4 methodology used by myself is discerning the damage to white matter, and its probable cause from  
5 neuroimaging. Among others, the University of California, San Francisco,<sup>10</sup> Cedars Sinai in California,  
6 the Brooke Army Medical Center, Harvard Medical School, University of Cincinnati, Duke University  
7 Medical Center utilize DTI-MRI sequence, *in conjunction with other sequences* to routinely determine  
8 white matter damage in patients with traumatic brain injury at the individual level, clinically." Solomon  
9 Declaration in Support of Plaintiff's Opposition to Defendants' MIL No. 13 ¶¶12 (emphasis in original).  
10 The fact that DTI-MRI is used to treat patients clinically is not necessarily evidence that DTI-MRI is  
11 reliable. See e.g. *Leahy* at 605–606 (Horizontal gaze nystagmus (HGN) used by police for 30 years; case  
12 law and scientific articles different views; remanded for *Kelly* hearing);<sup>11</sup> *In re Jordan R.* (2012) 205  
13 Cal.App.4th 111 (significant controversy within the relevant scientific community about the reliability of  
14 polygraph test results).  
15  
16

17 Plaintiffs also provide 10 expert declarations although the exhibits are not attached. None of  
18 them have been submitted under penalty of perjury under California law although one (Wu) was  
19 executed in California. None of them have case captions; thus, it is unclear the purpose of the  
20 declaration. Plaintiff is to provide further foundation for these declarations.  
21

22 One of the experts is Randell Benson, appears to be a leading authority on DTI-MRI. One court  
23 in analyzing a declaration submitted by him stated:

24 In his affidavit, Dr. Benson discusses some of the testing that he has conducted "to demonstrate  
25 the clinical validity and reliability of DTI in TBI" as part of his work with the U.S. Army  
26

---

27 <sup>10</sup> Defendants' deposition excerpt from Esposito, states UCSF does not read DTI-MRI for clinical uses.

28 <sup>11</sup> The use of HGN was later approved in *People v. Joehnk* (1995) 35 Cal.App.4th 1488, 1504-5 based upon three experts who testified that HGN was accepted in the relevant scientific community.

1 Telemedicine and Advanced Technology Research Command at a “Diffusion MRI TBI Roadmap  
2 Development Workshop.” Docket No. 116-1 at 11-12, ¶ 18. As part of his research for his  
3 presentation at that workshop, Dr. Benson found “excellent correlation between DTI and injury  
4 severity” and “repeatability of DTI for a single mTBI case scanned in two different cities.” *Id.* Dr.  
5 Benson also notes that “[o]ther speakers presented data showing the correlations of DTI with  
6 neurocognitive outcome and experience using DTI on Iraq war veterans.” *Id.* Dr. Benson states  
7 the known rate of error for DTI analysis is .4%, Docket No. 116-1 at 14, ¶ 28; however, he  
8 provides no support for this rate.

9 *White v. Deere & Company* (D. Colo., Feb. 8, 2016, No. 13-CV-02173-PAB-NYW) 2016 WL 462960, at

10 \*3. This court thus concluded: “The publications and workshops cited by Dr. Benson support the  
11 conclusion that DTI has been subjected to peer review and is generally accepted in the medical  
12 community as a tool for detecting TBI” even though there was not a known error rate. *Id.* at \*4.

13 Benson in his affidavit discusses his work studying brain injuries in former National Football  
14 League players, including testifying before the United States House Judiciary Committee (January 4,  
15 2010). Affidavit of Randall Benson, M.D. ¶2. He discusses a seminal peer-reviewed paper he published  
16 with E. Mark Haacke, Ph.D. *Id.* ¶4. Benson cites to over ten specific articles showing the reliability of  
17 DTI testing. *Id.* ¶42.

18 Andrew Walker, a board-certified neuroradiologist declares that the DTI-MRI “is FDA approved,  
19 recognized and recommended as a useful MRI technique by the American College of Radiology (ACR),  
20 American Society of Functional Neuroradiology (ASFNR), the Defense Centers of Excellence (DCOE),  
21 and by the United States Air Force Surgeon General’s Center for Excellence in Medical Multimedia  
22 (CEMM). DTI is one of the core MRI techniques used to evaluate TBI at NICOE, the Department Of  
23 Defense’s elite brain injury institute at Walter Reed National Medical Center.” Declaration of Andrew T.  
24 Walker, M.D. ¶3. Walker states that there is long-standing recognition of the clinical usefulness of DTI  
25 in the evaluation of TBI and standards in place for its use. *Id.* at ¶8.

26 Based upon these experts who have significant experience in the DTI-MRI field and work at well-  
27 respected medical centers, there is significant evidence that DTI-MRI is accepted in the scientific  
28 community. There is nothing in the testimony that suggests that they are interested, *i.e.*, have a financial

1 interest in promoting DTI-MRI.

2 **The Court Concludes that DTI-MRI Meets the Kelly Criteria**

3 Based upon the rulings of other courts, substantially all of whom have found DTI-MRI testing  
4 admissible, the consensus of the scientific literature and the disinterested experts, this Court after  
5 conducting its own review and analysis finds (subject to the confirmation set forth previously) that  
6 Plaintiff has met his burden in showing that DTI-MRI satisfies the *Kelly/Sargon* criteria and should be  
7 admitted into evidence. The case law, while not precedent, provides overriding support for the admission  
8 of the DTI-MRI. There is no question, as Defendants' exhibits demonstrate, that there is not unanimity  
9 in the scientific community about the reliability of DTI-MRI in a clinical setting. Unanimity, however, is  
10 not required—only consensus. *People v. Leahy* (1994) 8 Cal.4th 587, 612. Further, all studies have  
11 limitations and flaws, which should be taken into account, but the court should take into account the body  
12 of studies as a whole. *Cooper v. Takeda Pharmaceuticals America, Inc.* (2015) 239 Cal.App.4th 555,  
13 589.

14  
15  
16 In this case, there is significant peer-reviewed scientific literature that supports the reliability of  
17 DTI-MRI. All the expert testimony submitted to this Court opine that DTI-MRI is reliable in a clinical  
18 setting. These declarants all have sufficient training to express these opinions and most provide  
19 significant foundation for their opinions, including specific examples from their practice and reliance on  
20 the literature. While our Supreme Court in *Kelly* and *Sargon* make the trial court the gatekeeper for  
21 expert opinion, the trial court does not resolve scientific controversies, but conducts a circumscribed  
22 inquiry to determine “whether the matter relied on can provide a reasonable basis for the opinion or  
23 whether that opinion is based on a leap of logic or conjecture.” *Cooper v. Takeda Pharmaceuticals*  
24 *America, Inc.* (2015) 239 Cal.App.4th 555, 590.  
25  
26  
27  
28